Ichor Biologics

Ichor Biologics is a biotechnology startup with a focus on accelerating cures for infectious diseases. Specializing in the development of therapeutic monoclonal antibodies, the company has established a platform for characterizing and isolating pathogen-specific antibodies from convalescent patients. This approach allows them to preserve neutralizing and non-neutralizing antibody functions, increasing the likelihood of in-vivo efficacy. Since its founding in 2014, the company has targeted viral infections, such as Hantaviruses and HBV, as its initial disease targets.

Operating at the intersection of Biotechnology, Health Care, and Health and Wellness, Ichor Biologics is headquartered in the United States. Currently, there is no publicly available information on the last investment or the involved investors.